Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

IPD Analytics' Jeffrey Casberg Says IRA, PBM Legislation Reshape US Drug Costs

June 23rd 2024

By Cameron Santoro

Video

Jeffrey Casberg, RPh, MS, from IPD Analytics, explains why he believes policy changes and market forces are impacting the cost of drugs, including the Inflation Reduction Act (IRA) and pharmacy benefit manager (PBM) legislation.

No Differences in Treatment Persistence, Safety Detected for Anti-TNF Biosimilars vs Originators

June 22nd 2024

By Deana Ferreri, PhD

Article

A real-world study using data from the French National Health Data System, found no significant differences in treatment persistence or safety between anti-tumor necrosis factor (TNF)-α biosimilars and reference products in all indications of these biologics.

The Top 5 Biosimilar Articles for the Week of June 17

June 21st 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 17, 2024.

FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability

June 20th 2024

By Skylar Jeremias

Article

The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.

Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology

June 20th 2024

By Skylar Jeremias

Article

The broader adoption of biosimilar drugs has the potential to significantly reduce cancer care costs and improve patient access to more affordable treatments, benefiting both patients and payers. However, a recent review highlights that biosimilar uptake has been hindered by various economic, practical, attitudinal, and psychological factors.

Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity

June 19th 2024

By Cameron Santoro

Article

Part 2 of this series dives into the health care system, revealing financial hurdles that limit biosimilar access and ultimately hinder health equity.

British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years

June 18th 2024

By Skylar Jeremias

Article

British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.

BioRationality—How to Promote Science to Secure Waiver of Comparative Efficacy Testing for Biosimilars

June 17th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, makes suggestions for what arguments will help convince the FDA to waive clinical efficacy testing requirements for biosimilar approvals.

Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved

June 16th 2024

By Skylar Jeremias

Podcast

In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.

EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris

June 15th 2024

By Skylar Jeremias

Article

A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).